📰 Mood Scale News
Mood Scale News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mood Scale. Real-time updates on events, politics, business and more.
January 2, 2024
By Chris Wack Anavex Life Sciences shares were down 30% to $6.50 after the company said its Anavex 2-73 study missed a primary endpoint. The clinical-stage...
May 28, 2023
The initiative, facilitated in Bairnsdale, aims to help identify mums at risk of perinatal anxiety and depression.
May 16, 2023
*Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 *$44.4 million in cash and cash... | May 16, 2023
April 13, 2023
Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically... | April 13, 2023
April 12, 2023
Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically... | April 12, 2023
April 12, 2023
12.04.2023 - Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically significant and clinically meaningful improvements ... Seite 1
March 29, 2023
* Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 * European Commission granted orphan... | March 29, 2023
March 28, 2023
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted... | March 28, 2023
November 14, 2022
14.11.2022 - Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 $55.9 million in cash and cash equivalents at September 30, 2022; Cash runway into ...
October 17, 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 2022 National Organization for Rare Disorders (NORD) Rare Diseases and...